BRPI0807749B8 - composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos - Google Patents
composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicosInfo
- Publication number
- BRPI0807749B8 BRPI0807749B8 BRPI0807749A BRPI0807749A BRPI0807749B8 BR PI0807749 B8 BRPI0807749 B8 BR PI0807749B8 BR PI0807749 A BRPI0807749 A BR PI0807749A BR PI0807749 A BRPI0807749 A BR PI0807749A BR PI0807749 B8 BRPI0807749 B8 BR PI0807749B8
- Authority
- BR
- Brazil
- Prior art keywords
- prevention
- treatment
- compound
- acute
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSTO,COMPOSIÇÃO FARMACÊUTICA, E MÉTODO PARA A PREVENÇÃO, TRATAMENTO OU MELHORA, E, MÉTODO PARA A PREVENÇÃO, TRATAMENTO OU MELHORA DE DOENÇAS OU CONDIÇÕES DÉRMICAS, OU DISTÚRBIOS DE FERIDA CUTÂNEA AGUDOS OU CRÔNICAS. A presente invenção refere-se a um composto de acordo com a formula I, em que X, A, G, E, R2, R3 são como aqui mostrados; e sais farmaceuticamente aceitáveis dos mesmos, hidratos, N-óxidos e solvatos dos mesmos. A invenção refere-se ainda aos referidos compostos para o uso em terapia, a composições farmacêuticas que compreendem os referidos compostos, e a métodos para o tratamento de doenças, por exemplo, doenças dérmicas, com os referidos compostos, e ao uso dos referidos compostos na manufatura de medicamentos. .
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90384907P | 2007-02-28 | 2007-02-28 | |
| US60/903849 | 2007-02-28 | ||
| US94684907P | 2007-06-28 | 2007-06-28 | |
| US60/946849 | 2007-06-28 | ||
| PCT/DK2008/000080 WO2008104175A2 (en) | 2007-02-28 | 2008-02-26 | Novel phosphodiesterase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0807749A2 BRPI0807749A2 (pt) | 2014-06-17 |
| BRPI0807749B1 BRPI0807749B1 (pt) | 2021-01-05 |
| BRPI0807749B8 true BRPI0807749B8 (pt) | 2022-09-06 |
Family
ID=39415336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0807749A BRPI0807749B8 (pt) | 2007-02-28 | 2008-02-26 | composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8338431B2 (pt) |
| EP (1) | EP2114951B9 (pt) |
| JP (1) | JP5501770B2 (pt) |
| KR (1) | KR101571654B1 (pt) |
| AU (1) | AU2008221121B2 (pt) |
| BR (1) | BRPI0807749B8 (pt) |
| CA (1) | CA2676933C (pt) |
| CY (1) | CY1115227T1 (pt) |
| DK (1) | DK2114951T3 (pt) |
| ES (1) | ES2478670T3 (pt) |
| HK (1) | HK1138262A1 (pt) |
| HR (1) | HRP20140585T1 (pt) |
| IL (1) | IL200153A (pt) |
| MX (1) | MX2009009238A (pt) |
| MY (1) | MY150075A (pt) |
| NZ (1) | NZ578804A (pt) |
| PL (1) | PL2114951T3 (pt) |
| PT (1) | PT2114951E (pt) |
| RS (1) | RS53407B (pt) |
| RU (1) | RU2495043C2 (pt) |
| SI (1) | SI2114951T1 (pt) |
| WO (1) | WO2008104175A2 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2523119T3 (es) | 2009-12-22 | 2014-11-21 | Leo Pharma A/S | Nanocristales de monohidrato de calcipotriol |
| MX2012007229A (es) | 2009-12-22 | 2012-07-30 | Leo Pharma As | Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos. |
| WO2011076209A2 (en) | 2009-12-22 | 2011-06-30 | Leo Pharma A/S | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue |
| JP6174997B2 (ja) | 2010-06-24 | 2017-08-02 | レオ ファーマ アクティーゼルスカブ | ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物 |
| WO2013122855A1 (en) * | 2012-02-14 | 2013-08-22 | University Of Rochester | Methods of increasing lymphatic transport |
| WO2013182451A1 (en) * | 2012-06-04 | 2013-12-12 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| JP6367819B2 (ja) * | 2012-11-30 | 2018-08-01 | レオ ファーマ アクティーゼルスカブ | 活性化ｔ細胞におけるｉｌ−２２の発現の阻害方法 |
| DK3157930T3 (en) | 2014-06-23 | 2019-01-21 | Leo Pharma As | PROCEDURES FOR THE PREPARATION OF HETEROCYCLIC 1,3-BENZODIOXOL COMPOUNDS |
| ES2762987T3 (es) | 2015-06-19 | 2020-05-26 | Bristol Myers Squibb Co | Macrociclos de diamida como inhibidores del factor XIA |
| EP3390407B1 (en) * | 2015-12-18 | 2023-10-11 | UNION therapeutics A/S | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds |
| US10906915B2 (en) | 2016-12-12 | 2021-02-02 | Leo Pharma A/S | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors |
| EP3551632B1 (en) * | 2016-12-12 | 2024-06-12 | UNION therapeutics A/S | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors |
| DK3551634T3 (da) * | 2016-12-12 | 2021-06-14 | Union Therapeutics As | Substituerede pyrazoloazepin-8-oner og anvendelse deraf som phosphodiesterasehæmmere |
| AU2018286964B2 (en) * | 2017-06-20 | 2022-04-14 | UNION therapeutics A/S | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds |
| TW201919682A (zh) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Ｎｒｆ２路徑的新穎化合物 |
| FI3724196T3 (fi) | 2017-12-15 | 2023-01-31 | Substituoituja atsetidiinidihydrotienopyridiinejä ja niiden käyttö fosfodiesteraasin estäjinä |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9507297D0 (en) | 1995-04-07 | 1995-05-31 | Rh Ne Poulenc Rorer Limited | New composition of matter |
| US6514996B2 (en) * | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
| PT771794E (pt) * | 1995-05-19 | 2006-09-29 | Kyowa Hakko Kogyo Kk | Compostos heterociclicos contendo oxigenio |
| US5925636A (en) * | 1996-05-20 | 1999-07-20 | Darwin Discovery Limited | Benzofuran carboxamides and their therapeutic use |
| NZ334257A (en) * | 1996-08-28 | 2000-11-24 | Procter & Gamble | Spirocyclic metalloprotease inhibitors |
| CA2272327A1 (en) | 1996-11-19 | 1998-05-28 | Kyowa Hakko Kogyo Co., Ltd. | Oxygen-containing heterocyclic compounds |
| EP1029860B1 (en) * | 1997-10-01 | 2003-04-16 | Kyowa Hakko Kogyo Co., Ltd. | Benzofuran derivatives |
| DE19907038C2 (de) | 1999-02-19 | 2003-04-10 | Schott Glas | Transluzente oder opake Glaskeramik mit Hochquarz-Mischkristallen als vorherrschender Kristallphase und deren Verwendung |
-
2008
- 2008-02-26 AU AU2008221121A patent/AU2008221121B2/en active Active
- 2008-02-26 BR BRPI0807749A patent/BRPI0807749B8/pt active IP Right Grant
- 2008-02-26 PL PL08706922T patent/PL2114951T3/pl unknown
- 2008-02-26 NZ NZ578804A patent/NZ578804A/en unknown
- 2008-02-26 MX MX2009009238A patent/MX2009009238A/es active IP Right Grant
- 2008-02-26 US US12/528,649 patent/US8338431B2/en active Active
- 2008-02-26 WO PCT/DK2008/000080 patent/WO2008104175A2/en active Application Filing
- 2008-02-26 RS RS20140365A patent/RS53407B/en unknown
- 2008-02-26 ES ES08706922.5T patent/ES2478670T3/es active Active
- 2008-02-26 JP JP2009551915A patent/JP5501770B2/ja active Active
- 2008-02-26 MY MYPI20093168A patent/MY150075A/en unknown
- 2008-02-26 DK DK08706922.5T patent/DK2114951T3/da active
- 2008-02-26 CA CA2676933A patent/CA2676933C/en active Active
- 2008-02-26 RU RU2009135810/04A patent/RU2495043C2/ru active
- 2008-02-26 KR KR1020097018073A patent/KR101571654B1/ko active IP Right Grant
- 2008-02-26 SI SI200831224T patent/SI2114951T1/sl unknown
- 2008-02-26 EP EP08706922.5A patent/EP2114951B9/en active Active
- 2008-02-26 PT PT87069225T patent/PT2114951E/pt unknown
-
2009
- 2009-07-30 IL IL200153A patent/IL200153A/en active IP Right Grant
-
2010
- 2010-04-07 HK HK10103418.6A patent/HK1138262A1/xx unknown
-
2014
- 2014-06-17 CY CY20141100437T patent/CY1115227T1/el unknown
- 2014-06-23 HR HRP20140585AT patent/HRP20140585T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5501770B2 (ja) | 2014-05-28 |
| SI2114951T1 (sl) | 2014-08-29 |
| CA2676933C (en) | 2015-09-29 |
| BRPI0807749B1 (pt) | 2021-01-05 |
| MY150075A (en) | 2013-11-29 |
| AU2008221121A1 (en) | 2008-09-04 |
| WO2008104175A2 (en) | 2008-09-04 |
| WO2008104175A3 (en) | 2009-01-29 |
| EP2114951B9 (en) | 2015-09-02 |
| PT2114951E (pt) | 2014-07-17 |
| RS53407B (en) | 2014-10-31 |
| KR101571654B1 (ko) | 2015-11-25 |
| BRPI0807749A2 (pt) | 2014-06-17 |
| EP2114951A2 (en) | 2009-11-11 |
| CY1115227T1 (el) | 2017-01-04 |
| MX2009009238A (es) | 2009-09-08 |
| NZ578804A (en) | 2012-04-27 |
| AU2008221121B2 (en) | 2013-10-03 |
| IL200153A (en) | 2016-11-30 |
| EP2114951B1 (en) | 2014-04-09 |
| RU2009135810A (ru) | 2011-04-10 |
| US8338431B2 (en) | 2012-12-25 |
| JP2010519332A (ja) | 2010-06-03 |
| DK2114951T3 (da) | 2014-06-23 |
| CA2676933A1 (en) | 2008-09-04 |
| IL200153A0 (en) | 2010-04-15 |
| RU2495043C2 (ru) | 2013-10-10 |
| US20100099688A1 (en) | 2010-04-22 |
| HRP20140585T1 (hr) | 2014-09-12 |
| ES2478670T3 (es) | 2014-07-22 |
| KR20090126252A (ko) | 2009-12-08 |
| HK1138262A1 (en) | 2010-08-20 |
| PL2114951T3 (pl) | 2014-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0807749B8 (pt) | composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BRPI0714803B8 (pt) | compostos peptidomiméticos de smac, seus usos, e composição farmacêutica | |
| BR112013020620A2 (pt) | análogos de ácido 4-hidroxibutírico | |
| BRPI0507499A (pt) | composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5 | |
| BRPI0514841A (pt) | inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores | |
| BRPI0518846A2 (pt) | composto, composiÇço farmacÊutica, mÉtodos de tratar, ou reduzir o risco de doenÇas ou condiÇÕes em que inibiÇço da enzima mpo É benÉfica e de tratar, ou reduzir o risco de distérbios neuroinflamatàrios, uso de um composto, e, processo para a preparaÇço de um composto | |
| BR112014015845A8 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
| BR112014007721A2 (pt) | processos para preparar compostos úteis como inibidores de atr quinase | |
| BR112012010705A2 (pt) | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio | |
| BR112015014458A8 (pt) | compostos derivados de manose, seus intermediários, composição, uso e processos de preparação | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| BR112013029240A2 (pt) | derivados deuterados do ivacaftor | |
| BR112014013661A8 (pt) | derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| BR112014000371A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
| BR112012013854A2 (pt) | derivados de oxazina. | |
| BR112012020704A2 (pt) | compostos de pirrolopirimidina deuterados como inibidores de cdk4/6 | |
| BR112012008889A2 (pt) | compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes | |
| BR112018067930A2 (pt) | composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto. | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| UY33246A (es) | Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas | |
| BRPI1007092B8 (pt) | Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| BR112012027197A2 (pt) | combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25A | Requested transfer of rights approved |
Owner name: UNION THERAPEUTICS A/S (DK) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: LEO PHARMA A/S (DK) Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2671 DE 15/03/2022 POR TER SIDO INDEVIDA. |
|
| B25A | Requested transfer of rights approved |
Owner name: UNION THERAPEUTICS A/S (DK) |